Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$36.44
-2.2%
$47.72
$33.40
▼
$109.00
$1.27B1.44647,392 shs816,485 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-2.23%-3.67%+1.84%-50.52%-35.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$36.44
-2.2%
$47.72
$33.40
▼
$109.00
$1.27B1.44647,392 shs816,485 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-2.23%-3.67%+1.84%-50.52%-35.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.69
Moderate Buy$130.33257.67% Upside

Current Analyst Ratings Breakdown

Latest NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Lower Price TargetBuy$153.00 ➝ $149.00
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Initiated CoverageOverweight ➝ Neutral$53.00
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
UpgradeHold
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Initiated CoverageOutperform$130.00
10/9/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated RatingBuy$178.00
10/9/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Initiated CoverageMarket Perform
10/2/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated RatingBuy$185.00
9/25/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated RatingBuy$178.00
9/23/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Lower Price TargetNeutral$80.00 ➝ $50.00
9/16/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated RatingBuy$178.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$55.23M22.53N/AN/A$4.41 per share8.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$164.08M-$6.46N/AN/AN/A-339.67%-33.89%-24.86%N/A

Latest NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.07-$1.63+$0.44-$1.63$10.27 million$9.39 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
10.42
10.42

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
6334.14 million33.29 millionOptionable

Recent News About These Companies

Nektar Therapeutics Earnings Call Signals Clinical Momentum
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
Piper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) Stock Moved Down to Sell by Wall Street Zen
Nektar (NKTR) Q3 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
Nektar: Q3 earnings snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$36.44 -0.83 (-2.23%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$36.54 +0.11 (+0.29%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.